The executive director of the organization says gender inequality is one of the most important drivers of new infections, ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir ...

Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

1 This randomised controlled trial found that twice yearly injection of the drug lenacapavir for pre-exposure prophylaxis (PrEP) was 100% effective at preventing HIV infection in cisgender women and ...

The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two-yearly injectable HIV/ADS treatment as early as the summer 2025, a decision made by FDA after the ...

In a groundbreaking development for HIV prevention, the efficacy and safety of a six-monthly injection containing the antiretroviral drug lenacapavir have been confirmed through two pivotal studies.

Gilead Sciences’s decision to distribute HIV prevention drug lenacapavir made the news this month when they signed ...

Lenacapavir showed a 96% reduction in HIV infections, outperforming daily F/TDF in the PURPOSE 2 trial. The trial included a diverse global population, with 67% non-White participants, enhancing ...